Annals of Surgical Oncology

, Volume 25, Supplement 3, pp 920–921 | Cite as

ASO Author Reflections: Implementing a Program of Talimogene laherparepvec

  • Frances CollichioEmail author
ASO Author Reflections



Frances Collichio does research at the University of North Carolina that is supported by Amgen, Novartis and Merck.


  1. 1.
    Andtbacka RH, Kaufman HL, Collichio F, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33(25):2780–8.CrossRefGoogle Scholar
  2. 2.
    Hoffner B, Iodice GM, Gasal E. Administration and handling of Talimogene laherparepvec: an intralesional oncololytic immunotherapy for melanoma. Oncol Nurs Forum. 2016;43(2):219–26.CrossRefGoogle Scholar
  3. 3.
    Wolchok JD, Hoos A, O’Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:7412–20.CrossRefGoogle Scholar
  4. 4.
    Kaufman HL, Andtbacka RH, Collichio FA, et al. Durable response rate as an endpoint in cancer immunotherapy: Insight from oncolytic virus clinical trials. J Immunother Cancer. 2017;5:72–81.CrossRefPubMedCentralGoogle Scholar
  5. 5.
    Collichio F, Burke L, Proctor A, et al. Implementing a program of Talimogene laherparepvec. Ann Surg Oncol. 2018;25:1828–35.CrossRefGoogle Scholar
  6. 6.
    Iafolla MA, Selby H, Warner K, et al. Rational design and identification of immune-oncology drug combinations. Ejcancer. 2018;2:38–57.Google Scholar
  7. 7.
    Ribas A, Dummer R, Puzano I, et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell. 170(6):1109–19.e10.
  8. 8.
    National Cancer Institute. Clinical Trials Information. Accessed 8 Oct 2018.

Copyright information

© Society of Surgical Oncology 2018

Authors and Affiliations

  1. 1.Department of Medicine, Division of Hematology-OncologyThe University of North CarolinaChapel HillUSA

Personalised recommendations